Lung Cancer

touchONCOLOGY joins Dr Paula Ugalde (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) at WCLC 2021 to discuss her presentation on screening, incidental nodules and adjuvant therapy for early-stage lung cancer. Questions 1. Early detection of lung cancer improves disease outcomes – when and in which patients do you perform screening? (00:15-00:46) 2. […]

touchONCOLOGY joins Prof Antoinette Wozniak (UPMC Hillman Cancer Center, Pittsburgh, PA, USA) at WCLC 2021 to discuss the challenges of treating small cell lung cancer and the most important recent advances. Questions 1. Please can you outline the current prognosis for patients with small cell lung cancer (SCLC)? (00:26-02:37) 2. In your opinion, what are […]

touchONCOLOGY joins Editorial Board Member Prof Antoinette Wozniak (UPMC Hillman Cancer Center, Pittsburgh, PA, USA) at WCLC 2021 to discuss her highlights of the conference this year. Question What have been your particular highlights of the World Conference on Lung Cancer 2021? Disclosures: Antoinette Wozniak has no financial or non-financial conflicts of interest to declare […]

touchONCOLOGY joins Dr Luis Raez (Memorial Cancer institute, Memorial Healthcare System, Hollywood, FL, USA) at WCLC 2021 to discuss the latest advances in immunotherapies and targeted therapies in lung cancer. Question What have been your highlights from this conference? Disclosures: Luis Raez has no financial or non-financial conflicts of interest to declare in relation to […]

touchONCOLOGY joins Dr Luis Raez (Memorial Cancer institute, Memorial Healthcare System, Hollywood, FL, USA) at WCLC 2021 to discuss the latest advances in immunotherapies and targeted therapies in lung cancer. Questions 1. Despite advances in the treatment of most types of cancer, lung cancer prognosis remains poor – what types of immunotherapies and targeted therapies […]

touchONCOLOGY joins Professor Myung-Ju Ahn (Samsung Medical Center, Seoul, South Korea) at WCLC 2021 to discuss the AURA3 trial of osimertinib as a treatment for EGFR-mutant non-small cell lung cancer. Abstract: FP16.03 ClinicalTrials.gov Identifier: NCT02151981 Questions 1. What are the strengths and limitations of osimertinib as a treatment for EGFR-mutant non-small cell lung cancer? (00:17-01:13) […]

touchONCOLOGY joins Dr Valsamo Anagnostou (Johns Hopkins University School of Medicine, Baltimore, MD, USA ) at WCLC 2021 to discuss her presentation on the circulating tumor DNA biomarker-directed blood test and immune checkpoint inhibitor therapy in people with advanced non-small cell lung cancer. Clinical Trial Registry Identifiers: CRI-CCTG0002/BR.36, NCT04093167. Questions 1. What are the major […]

touchONCOLOGY joins Dr Alexander Spira (Virginia Cancer Specialists, Fairfax, VA, USA) at WCLC 2021 to discuss the current, ongoing PERLA phase II clinical trial, that explores the efficacy of dostarlimab + chemotherapy versus pembrolizumab + chemotherapy in metastatic non-squamous non-small cell lung cancer. ClinicalTrials.gov Identifier: NCT04581824  Questions 1. What are the potential advantages of dostarlimab […]

Cancer treatment has expanded rapidly in recent years as advancements in the fields of tumour biology and molecular diagnostics have informed the development of targeted therapies, improving survival in patients with oncogene-addicted cancers with therapeutically relevant molecular lesions. Osimertinib has become the standard-of-care treatment in the USA and elsewhere for classical epidermal growth factor receptor […]